Bibliothèque des systèmes de santé de l'OMS
Changer vers la version anglaiseChanger vers la version espagnole
WHO Good Governance for Medicines Programme: An Innovative Approach to Prevent Corruption in the Pharmaceutical Sector. Compilation of Country Case Studies and Best Practices. World Health Report (2010), Background Paper, No 25
(2010; 27 pages)


Corruption is a major obstacle to strengthening pharmaceutical systems and increasing access to quality medicines. In an effort to address this complex and multi-faceted challenge, WHO launched the Good Governance for Medicines (GGM) in 2004, its initiative to concretely address the need for transparency and preventing corruption in the health sector. Initially a pilot project in four Asian countries, the GGM grew rapidly to become a global programme implemented in 26 countries, gaining momentum in Ministries of Health (MOH). This paper is intended to share country experiences in implementing the GGM programme in the last six years. It is based on information received from countries that have already implemented the GGM and have documented their experiences. A brief description of activities undertaken in these countries is presented below, focusing mainly on interventions at the country level that have led to changes and improvements in the pharmaceutical sector. This paper also offers a number of analyses on "best practices" and "lessons learnt" with a view to inspiring health professionals, managers and policy makers in other countries in their efforts to strengthen health and pharmaceutical systems, as well as to reach universal health coverage and increase access to quality essential medicines. It is hoped also that this paper will serve as a contribution to move forward the international anti-corruption agenda within the pharmaceutical sector and beyond...

Dernière mise à jour: le 4 mai 2012